Address unmet medical need
One of the critical challenges in oncology is the low target binding capacity of current therapies, where only about 1% of the antibody specifically binds to tumor in ADCs.
SC-101 addresses this issue with a higher toxin loading capacity and superiordrug penetrance within tumor tissues. The smaller molecular weight of PDCs increases drug loading capacity and enhances drug penetration in tumors.Notably, we achieved Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA) in China for SC-101. Our first-in-human trial, registered as NCT06220838, is currently ongoing, with clinical data expected later this year.Additionally, we received IND clearance from the U.S. Food and Drug Administration (FDA) in May 2024. SC-101 (Nectin-4–targeting PDC) granted U.S. FDA Orphan Drug Designation for esophageal cancer in April 2025.
In Augest 2024, we achieved Investigational New Drug (IND) approval from NMPA in China for SC-102 and received U.S. FDA IND clearance in May 2025: .
